Payment overview · 2025
General Payments
$154.56
9 reported records · 7 companies
Healthcare provider profile · identity verified
David M Campanelli, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW CANTON, VA · NPI 1790763829
Verified facts
What the public records show
CMS Open Payments records show David M Campanelli, MD received $154.56 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Mounjaro, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.98 | 22.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.70 | 17.9% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $24.91 | 16.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.92 | 14.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.60 | 10.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.76 | 9.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.69 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $154.56 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.70 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.70 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| FLULAVAL QUADRIVALENT Normalized: flulaval quadrivalent |
Biological | GlaxoSmithKline, LLC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 44 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
37 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
104 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
44 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 529 | 145 |
| Lisinopril | Lisinopril | 347 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 328 | 92 |
| Omeprazole | Omeprazole | 322 | 81 |
| Metformin Hcl Er | Metformin Hcl | 302 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 51 |
| Gabapentin | Gabapentin | 218 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 64 |
| Losartan Potassium | Losartan Potassium | 188 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 56 |
| Furosemide | Furosemide | 169 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 52 |
| Carvedilol | Carvedilol | 153 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 47 |
| Eliquis | Apixaban | 148 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 143 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 34 |
| Montelukast Sodium | Montelukast Sodium | 139 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 138 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 39 |
| Jardiance | Empagliflozin | 119 | 32 |
| Januvia | Sitagliptin Phosphate | 118 | 29 |
| Spironolactone | Spironolactone | 118 | 32 |
| Potassium Chloride | Potassium Chloride | 115 | 28 |
| Glimepiride | Glimepiride | 110 | 31 |
| Prednisone | Prednisone | 109 | 70 |
| Allopurinol | Allopurinol | 108 | 32 |
| Clonazepam | Clonazepam | 107 | 13 |
| Trulicity | Dulaglutide | 104 | 13 |
| Finasteride | Finasteride | 99 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 23 |
| Famotidine | Famotidine | 97 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 24 |
| Atenolol | Atenolol | 81 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 26 |
| Lorazepam | Lorazepam | 79 | 14 |
| Meloxicam | Meloxicam | 72 | 20 |
| Trazodone Hcl | Trazodone Hcl | 68 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 19 |
| Clotrimazole | Clotrimazole | 64 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 18 |
| Pregabalin | Pregabalin | 63 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 63 | 16 |
| Ibuprofen | Ibuprofen | 61 | 13 |
| Tradjenta | Linagliptin | 61 | 19 |
| Ezetimibe | Ezetimibe | 60 | 16 |
| Metformin Hcl | Metformin Hcl | 60 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 19 |
| Fluconazole | Fluconazole | 57 | 32 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 13 |
| Colchicine | Colchicine | 53 | 16 |
| Baclofen | Baclofen | 52 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 52 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 13 |
| Azithromycin | Azithromycin | 49 | 42 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 26 |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 44 | 44 |
| Cephalexin | Cephalexin | 44 | 33 |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 34 |
| Mirtazapine | Mirtazapine | 41 | 11 |
| Simvastatin | Simvastatin | 41 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 34 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 29 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | 12 |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Nitroglycerin | Nitroglycerin | 27 | 21 |
| Latanoprost | Latanoprost | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 17 |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Metronidazole | Metronidazole | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $154.56 · 9 records | PFIZER INC. | ABRYSVO, AREXVY, CAPVAXIVE, COMIRNATY, FLULAVAL QUADRIVALENT, FREESTYLE LIBRE 3, GARDASIL 9, M-M-R II, MOUNJARO, PENBRAYA, PREVNAR 20, SHINGRIX, VAXNEUVANCE, VIVITROL, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error